SWM
VRTX icon

Spire Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Spire Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$970K Buy
1,953
+48
+3% +$21.3K 0.03% 395
2026
Q1 		$850K Sell
1,905
-50
-3% -$23.3K 0.03% 414
2025
Q4 		$886K Sell
1,955
-381
-16% -$164K 0.03% 417
2025
Q3 		$915K Sell
2,336
-8,962
-79% -$3.75M 0.03% 394
2025
Q2 		$4.91M Sell
11,298
-7,278
-39% -$3.35M 0.18% 109
2025
Q1 		$9.01M Buy
18,576
+72
+0.4% +$33.6K 0.29% 70
2024
Q4 		$7.45M Sell
18,504
-219
-1% -$102K 0.23% 92
2024
Q3 		$8.71M Sell
18,723
-1,031
-5% -$495K 0.29% 75
2024
Q2 		$9.25M Sell
19,754
-301
-2% -$131K 0.33% 62
2024
Q1 		$20.1M Sell
20,055
-596
-3% -$252K 0.36% 60
2023
Q4 		$8.98M Buy
20,651
+4,274
+26% +$1.58M 0.3% 71
2023
Q3 		$5.69M Sell
16,377
-6,796
-29% -$2.38M 0.22% 90
2023
Q2 		$8.15M Sell
23,173
-1,591
-6% -$536K 0.3% 72
2023
Q1 		$7.8M Buy
24,764
+3,664
+17% +$1.1M 0.3% 70
2022
Q4 		$6.09M Sell
21,100
-676
-3% -$206K 0.34% 67
2022
Q3 		$6.3M Sell
21,776
-5,276
-20% -$1.52M 0.38% 64
2022
Q2 		$7.62M Sell
27,052
-11,007
-29% -$2.95M 0.31% 83
2022
Q1 		$9.94M Buy
38,059
+35,416
+1,340% +$8.41M 0.27% 101
2021
Q4 		$580K Buy
2,643
+1,727
+189% +$336K 0.01% 642
2021
Q3 		$166K Sell
916
-450
-33% -$87.9K ﹤0.01% 996
2021
Q2 		$275K Sell
1,366
-3,362
-71% -$703K 0.01% 812
2021
Q1 		$1.02M Buy
+4,728
New +$1.04M 0.03% 431

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Spire Wealth Management's VRTX Position: Q2 2026 in Review

Spire Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.5% in Q2 2026, buying an estimated $21.3K and bringing the position to 1,953 shares worth $970K. The position accounts for 0.03% of the portfolio, ranked #395.

Spire Wealth Management first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $20.1M in Q1 2024. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Spire Wealth Management held 1,953 shares of Vertex Pharmaceuticals worth $970K as of Q2 2026.
  • Spire Wealth Management bought 48 Vertex Pharmaceuticals shares in Q2 2026, an estimated $21.3K.
  • Vertex Pharmaceuticals made up 0.03% of Spire Wealth Management's portfolio in Q2 2026, its #395 holding.
  • Spire Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Spire Wealth Management's Vertex Pharmaceuticals position peaked at $20.1M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.